The slightly longer OS for combination therapy compared to monotherapy in NSQ NSCLC with PD-L1 ≥50% suggests the need for further investigations of optimal treatment in advanced NSCLC with high PD-L1 expression in prospective trials, and exploration of patient characteristics that may guide the choice of therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.